跳至主要内容
临床试验/IRCT201012295496N1
IRCT201012295496N1已完成1 期

Assessing the effects of not using maintnance dose o atracurium dring open hear sugery in Coronary Artery Bypass Graft patiants

Tehran University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Inclusion criterion: 18-75y old patients planned to go under Coronary Artery Bypass Graft surgery.
  • Exclusion criteria: myopathy; neuropathy; sever pulmonary or renal disease; emergency surgery and opium addiction

排除标准

  • 未提供

研究者

相似试验

已完成
1 期
Safety Evaluation of the Maintenance treatment of Sorafenib in Hepatocellular carcinoma patients with Tumor thrombus after palliative surgeryTo evaluate the safety of sorafenib as a maintenance therapy after the surgical resection of hepatocellular carcinoma (HCC) with macroscopic vascular invasion (Vp, Vv, B).
JPRN-UMIN000005910Tokyo University Hospital12
已完成
不适用
Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis.Rheumatoid Arthritis
JPRN-UMIN000013362Takarazuka city hospital60
进行中(未招募)
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem.MedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000013103
EUCTR2010-023407-95-DEF. Hoffmann-La Roche Ltd700
进行中(未招募)
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.
EUCTR2010-023407-95-ATF. Hoffmann-La Roche Ltd700
进行中(未招募)
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system.MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000013103
EUCTR2010-023407-95-GBF. Hoffmann-La Roche Ltd692